Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Good long-term outlook for hairy-cell leukaemia

09 Jun 2020

Hairy-cell leukaemia (HCL) has favourable long-term prognosis, with a good survival outlook despite a high relapse rate, a recent study has found.

A total of 279 HCL patients (median age, 59 years) were enrolled and followed for a median of 127 months. Eighty-five had familial histories of malignancies. Over the observation period, 99 patients (36 percent) experienced at least one new event, defined as new relapses, death or second cancers developing since the first analysis.

A total of 130 new events were reported, almost half of which (n=60) were relapses. Fifty-four patients had relapse episode, while six had two episodes. In addition, there were 25 solid second cancers, 12 haematological malignancies, and 33 new deaths.

At the final follow-up, 229 participants were still alive, majority of whom (84 percent; n=193) were in complete remission. Nineteen patients were in partial remission, and 10 had progressive disease. Status was unknown in seven patients. The median overall survival was 27 years, and the relapse-free survival time was 7 years.

Purine analogues (PNAs) were the most common form of first-line therapy (n=208; 75 percent), frequently administered as either cladribine (n=159) or pentostatin (n=49). This appeared to be a highly effective treatment regimen, resulting in a 100-percent overall response rate for all PNA-treated participants.

“In this 10-year follow-up analysis, we confirmed the favourable prognosis of HCL,” said researchers. “In our cohort, there was no difference between patients who switched or did not switch between PNAs from the first to the second line.

“Interestingly, we found a relatively higher risk of solid cancers and haematological malignancies in HCL patients,” they added. “[I]t seems that PNAs are not a risk factor for second cancers.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.